Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome
NCT01559961
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Interstitial Cystitis
Interventions
DRUG:
TTI-1612
Sponsor
Trillium Therapeutics Inc.